

Generic Contrast Agents

Our portfolio is growing to serve you better. Now you have a *choice*.



[VIEW CATALOG](#)

AJNR

Reply:

R.V. Chandra, J. Maingard, H. Asadi, L.-A. Slater and J.A. Hirsch

AJNR Am J Neuroradiol 2018, 39 (10) E110-E111

doi: <https://doi.org/10.3174/ajnr.A5781>

<http://www.ajnr.org/content/39/10/E110>

This information is current as
of May 8, 2025.

REPLY:

We thank Braillon and Bewley for their interest in our article, “Vertebroplasty and Kyphoplasty for Osteoporotic Vertebral Fractures: What Are the Latest Data?” The stated aim of this article was to provide an update to clinicians on the evolution of evidence for reduction in pain and disability from vertebroplasty and kyphoplasty for osteoporotic vertebral fractures and, in particular, highlight the limitations of the various prospective randomized controlled trials (RCTs). The most recent trial, A Randomised Sham-Controlled Trial of Vertebroplasty for Painful Acute Osteoporotic Vertebral Fractures (VERTOS IV)¹ had not been published at the time this review was conducted. Notably, there are important differences in the enrolled patient cohorts between A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures (VAPOUR) and VERTOS IV, which again highlight the challenge in the interpretation of outcomes from these procedures.²

Apart from the RCTs, there are also strong signals of benefit from large national or insurance-based-claims datasets from Germany, Sweden, France, Taiwan, and the United States.^{3–9} In one of the largest analyses of more than 2 million patients during 10 years from the US Medicare dataset, there was a strong signal of reduced mortality after vertebral augmentation compared with medical management.⁸ This signal of survival benefit has been replicated in further analysis of German⁵ and Taiwanese⁷ health insurance datasets. In addition, various national and medical societies have varied in their interpretation of the evidence, depending on when they examined the literature.^{10–12} Most notably, the National Institute for Health and Care Excellence, which provides evidence-based guidance and advice to the National Health Service in the United Kingdom, recommends vertebroplasty and kyphoplasty as treatment options for patients with severe pain after a recent osteoporotic vertebral compression fracture and concluded that it was reasonable to assume that the procedures reduce mortality.¹³

Akin to many other areas in medicine, clinicians must integrate their clinical expertise with patient values and interpretation of the research evidence to provide optimized and meaningful care. For years, the results from the various RCTs have shown that vertebroplasty and kyphoplasty are best considered for patients with severe pain and disability and only after rigorous clinical and advanced imaging selection. Moreover, earlier treatment (potentially <3 weeks from fracture onset) may provide the best chance of benefit. Important questions remain unanswered; for example, what are the implications of the progressive height loss evident in untreated-versus-cemented levels in VERTOS IV and VAPOUR? Does this prevention of height loss help explain the mortality benefit observed in almost all claims-based studies? We concur with Braillon and Bewley that new patients should be included in further RCTs to clarify the role of these procedures or included in large registries in which data can be pooled and additional meaningful conclusions reached.

REFERENCES

1. Firanescu CE, de Vries J, Lodder P, et al. **Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial.** *BMJ* 2018;361:k1551 CrossRef Medline

2. Clark W, Bird P, Gonski P, et al. **Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial.** *Lancet* 2016; 388:1408–16 CrossRef Medline
3. Edidin AA, Ong KL, Lau E, et al. **Morbidity and mortality after vertebral fractures: comparison of vertebral augmentation and non-operative management in the Medicare population.** *Spine* 2015;40: 1228–41 CrossRef Medline
4. Kanis JA, Oden A, Johnell O, et al. **Excess mortality after hospitalisation for vertebral fracture.** *Osteoporos Int* 2004;15:108–12 CrossRef Medline
5. Lange A, Kasperk C, Alvares L, et al. **Survival and cost comparison of kyphoplasty and percutaneous vertebroplasty using German claims data.** *Spine* 2014;39:318–26 CrossRef Medline
6. Lau E, Ong K, Kurtz S, et al. **Mortality following the diagnosis of a vertebral compression fracture in the Medicare population.** *J Bone Joint Surg Am* 2008;90:1479–86 CrossRef Medline
7. Lin JH, Chien LN, Tsai WL, et al. **Early vertebroplasty associated with a lower risk of mortality and respiratory failure in aged patients with painful vertebral compression fractures: a population-based cohort study in Taiwan.** *Spine J* 2017;17:1310–18 CrossRef Medline
8. Ong KL, Beall DP, Frohbergh M, et al. **Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?** *Osteoporos Int* 2018;29:375–83 CrossRef Medline
9. Zampini JM, White AP, McGuire KJ. **Comparison of 5766 vertebral compression fractures treated with or without kyphoplasty.** *Clin Orthop Relat Res* 2010;468:1773–80 CrossRef Medline
10. Barr JD, Jensen ME, Hirsch JA, et al; Society of Interventional Radiology, American Association of Neurological Surgeons, Congress of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, American Society of Spine Radiology, Canadian Interventional Radiology Association, Society of Neurointerventional Surgery. **Position statement on percutaneous vertebral augmentation: a consensus statement developed by the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), American College of Radiology (ACR), American Society of Neuroradiology (ASNR), American Society of Spine Radiology (ASSR), Canadian Interventional Radiology Association (CIRA), and the Society of NeuroInterventional Surgery (SNIS).** *J Vasc Interv Radiol* 2014;25:171–81 CrossRef Medline
11. Chandra RV, Meyers PM, Hirsch JA, et al; Society of NeuroInterventional Surgery. **Vertebral augmentation: report of the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery.** *J Neurointerv Surg* 2014;6:7–15 CrossRef Medline
12. Tsoumakidou G, Too CW, Koch G, et al. **CIRSE guidelines on percutaneous vertebral augmentation.** *Cardiovasc Intervent Radiol* 2017;40:331–42 CrossRef Medline
13. National Institute for Health and Care Excellence. **Technology appraisal guidance TA279. Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures.** April 24, 2013; <https://www.nice.org.uk/guidance/ta279>. Accessed July 14, 2018

R.V. Chandra

Interventional Neuroradiology Unit, Monash Imaging
Monash Health
Melbourne, Victoria, Australia
Faculty of Medicine, Nursing and Health Sciences
Monash University
Melbourne, Victoria, Australia

J. Maingard

Interventional Neuroradiology Service, Department of Radiology
Austin Hospital
Melbourne, Victoria, Australia
School of Medicine
Faculty of Health, Deakin University
Warrnambool, Victoria, Australia

 H. Asadi

Interventional Neuroradiology Unit, Monash Imaging
Monash Health
Melbourne, Victoria, Australia
Interventional Neuroradiology Service, Department of Radiology
Austin Hospital
Melbourne, Victoria, Australia
School of Medicine
Faculty of Health, Deakin University
Waurin Ponds, Victoria, Australia

 L.-A. Slater

Interventional Neuroradiology Unit, Monash Imaging
Monash Health
Melbourne, Victoria, Australia
Faculty of Medicine, Nursing and Health Sciences,
Monash University
Melbourne, Victoria, Australia

 J.A. Hirsch

Neuroendovascular Program
Massachusetts General Hospital, Harvard Medical School
Boston, Massachusetts